Ceftobiprole

Ceftobiprole (Zeftera/Zevtera) is a fifth-generation cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, Pseudomonas aeruginosa, and enterococci. It was discovered by Basilea Pharmaceutica and was developed by Johnson & Johnson Pharmaceutical Research and Development. It has been shown to be statistically noninferior to the combination of vancomycin and ceftazidime for the treatment of skin and soft tissue infections.